Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

Jorge E. Cortes, Carlos A. Jimenez, Michael J. Mauro, Alex Geyer, Javier Pinilla-Ibarz, B. Douglas Smith

Research output: Contribution to journalReview article

Abstract

Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.

Original languageEnglish (US)
Pages (from-to)78-82
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Pleural Effusion
Morbidity
Dasatinib
Therapeutics

Keywords

  • Adverse events
  • Algorithms
  • BCR-ABL1
  • Fluid retention
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase : Identification and Management. / Cortes, Jorge E.; Jimenez, Carlos A.; Mauro, Michael J.; Geyer, Alex; Pinilla-Ibarz, Javier; Smith, B. Douglas.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, No. 2, 01.02.2017, p. 78-82.

Research output: Contribution to journalReview article

Cortes, Jorge E. ; Jimenez, Carlos A. ; Mauro, Michael J. ; Geyer, Alex ; Pinilla-Ibarz, Javier ; Smith, B. Douglas. / Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase : Identification and Management. In: Clinical Lymphoma, Myeloma and Leukemia. 2017 ; Vol. 17, No. 2. pp. 78-82.
@article{b9f63f70ae8e43a38199a81e4d8fb934,
title = "Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management",
abstract = "Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.",
keywords = "Adverse events, Algorithms, BCR-ABL1, Fluid retention, Tyrosine kinase inhibitor",
author = "Cortes, {Jorge E.} and Jimenez, {Carlos A.} and Mauro, {Michael J.} and Alex Geyer and Javier Pinilla-Ibarz and Smith, {B. Douglas}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.clml.2016.09.012",
language = "English (US)",
volume = "17",
pages = "78--82",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase

T2 - Identification and Management

AU - Cortes, Jorge E.

AU - Jimenez, Carlos A.

AU - Mauro, Michael J.

AU - Geyer, Alex

AU - Pinilla-Ibarz, Javier

AU - Smith, B. Douglas

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.

AB - Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.

KW - Adverse events

KW - Algorithms

KW - BCR-ABL1

KW - Fluid retention

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85011636450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011636450&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2016.09.012

DO - 10.1016/j.clml.2016.09.012

M3 - Review article

C2 - 28082112

AN - SCOPUS:85011636450

VL - 17

SP - 78

EP - 82

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -